Posted by Michael Wonder on 31 Jul 2019
Health Canada approves Vitrakvi (larotrectinib), the first tumour agnostic cancer treatment for advanced solid tumours harbouring an NTRK gene fusion
30 July 2019 - Bayer announced today that there is now a treatment in Canada for tyrosine receptor kinase fusion protein-driven childhood and adult cancers.
Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusions can result in the production of TRK fusion proteins that can lead to uncontrolled cell growth and cancer.
Health Canada issued a Notice of Compliance with Conditions (NOC/c) for Vitrakvi (larotrectinib). Virtakvi is approved for the treatment of adult and pediatric patients with solid tumours that have an NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory treatment options. Treatment with Vitrakvi should be initiated following confirmation of an NTRK gene fusion in a tumour specimen using a validated test.
